Motoneuron (MN) cell death is the histopathologic hallmark of spinal muscular atrophy (SMA), although MN loss seems to be a late event. Conversely, disruption of afferent synapses on MNs has been shown to occur early in SMA. Using a mouse model of severe SMA (SMN$7), we examined the mechanisms involved in impairment of central synapses. We found that MNs underwent progressive degeneration in the course of SMA, with MN loss still occurring at late stages. Loss of afferent inputs to SMA MNs was detected at embryonic stages, long before MN death. Reactive microgliosis and astrogliosis were present in the spinal cord of diseased animals after the onset of MN loss. Ultrastructural observations indicate that dendrites and microglia phagocytose adjacent degenerating presynaptic terminals. Neuronal nitric oxide synthase was upregulated in SMN$7 MNs, and there was an increase in phosphorylated myosin light chain expression in synaptic afferents on MNs; these observations implicate nitric oxide in MN deafferentation and suggest that the RhoA/ROCK pathway is activated. Together, our observations suggest that the earliest change occurring in SMN$7 mice is the loss of excitatory glutamatergic synaptic inputs to MNs; reduced excitability may enhance their vulnerability to degeneration and death.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive disease that affects > motoneurons (MNs) in the spinal cord and causes muscular weakness and atrophy of limb and trunk muscles. With an incidence of 1 in 6,000 to 10,000 live births and a carrier frequency of 1 in 35 to 50, this neurodegenerative disease is the leading genetic cause of early childhood lethality (1, 2) . Spinal muscular atrophy is caused by a homozygous deletion or specific mutations in the SMN1 (survival of motor neuron-1) gene, which is localized in the telomeric region of chromosome 5 (3) . SMN1 codes for survival motor neuron (SMN) protein, which plays an essential role in the assembly of small nuclear ribonucleoproteins necessary for the preYmessenger RNA splicing machinery (4) . In humans, an additional centromeric gene, SMN2, also produces low levels of functional SMN. Whereas SMN1 generates full-length SMN, a single nucleotide polymorphism in SMN2 results in the exclusion of exon 7 from most transcripts, producing a high amount of unstable truncated SMN (SMN$7) protein, which is rapidly degraded (5) . The low levels (È10%Y20%) of functional full-length SMN generated by SMN2 are insufficient to compensate for the lack of SMN1 function. Thus, in the absence of a functional SMN1 gene, the severity of the disease correlates with the copy numbers of the SMN2 gene (6) . In contrast with humans, mice have a single SMN (Smn) gene, and its inactivation leads to embryonic lethality (7) . One of the most widely used models of SMA is a mouse model lacking the endogenous Smn gene but with 2 copies of a transgenic human SMN2 and an additional transgene expressing high levels of the human SMN transcript lacking exon 7 (SMN$7). Mice with this genotype (Smn j/j ; SMN2 +/+ ;SMN$7 +/+ )V''SMN$7'' miceVexhibit a severe postnatal SMA phenotype with a median life span of approximately 2 weeks (6, 8) .
Although SMN is a ubiquitous protein, its low expression levels predominantly lead to damage of lower MNs (9) . Interestingly, recent reports indicate that SMN is involved in U12-dependent splicing events, which are important for MN function (10) . However, only a modest loss of MNs has been found in SMA mouse models at end stages of diseases and in patients with SMA (6, 11Y16) . This suggests that MN death is a late event in the pathogenesis of this disorder (17) .
Astrocytes and microglia respond profoundly to neuronal injury and undergo a series of metabolic and morphologic changes known as ''reactive gliosis'' (18) ; glial activation often occurs in parallel with either nonspecific (innate) or specific (adaptive) immune responses within the CNS in a process termed ''neuroinflammation.'' In recent years, neuroinflammation has been thought to play an active role in the pathology of different neurodegenerative diseases, including Alzheimer disease, Huntington disease, Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) (19Y24). In addition to MN loss, astroglial or microglial activation is observed early in the spinal cord of patients with SMA and may be another important pathologic aspect of this disease (12, 25Y27) . Astrocytes and microglia may propagate injury and, under certain circumstances, may even initiate neurodegeneration, but the pathologic roles of glial cells in SMA have not been studied in depth.
Glial cells play important roles in the formation, function, and elimination of synapses under normal and pathologic conditions (28) . Different studies performed on SMA mouse models have reported synaptic defects at the neuromuscular junction, including impaired maturation, structural disruption and denervation, deficient neurotransmitter release, and neurofilament accumulation (9, 12, 15, 17, 25, 29Y32) . Additional studies indicate that defects in central synapses are also involved in SMA pathogenesis (13, 25, 33, 34) . The molecular bases underlying these synaptic alterations are poorly defined. It has been proposed that nitric oxide (NO) plays a role in synaptic remodeling (35) and that expression of neuronal NO synthase (nNOS) induces synapse loss on adult and neonatal MNs. Nitric oxideYdirected synapse elimination is mediated by the activation of the small Rho GTPase RhoA and its major effector Rho kinase ROCK by inducing neurite retraction (36) . The role of nNOS in SMA synaptic defects has not been investigated.
In the present study, we used the SMN$7 mouse model to examine the contribution of astroglial and microglial cells to SMA spinal cord pathology, including degenerative changes in MN synaptic inputs. In addition, we show that nNOS is upregulated and the RhoA/ROCK pathway is activated during central synaptic remodeling in SMA.
MATERIALS AND METHODS

Animals
Mice were purchased from The Jackson Laboratory (Sacramento, CA (6) . Age-matched WT littermates of mutant animals were used as controls.
Mice were anesthesized with an intraperitoneal injection of 2% pentobarbital (1 mL/10 g body weight) and, except for electron microscopy studies, killed by quick decapitation. The WT and SMN$7 animals analyzed were pooled in 6 different groups as follows: embryonic day (E) 18, postnatal day (P) 0Y1, P4Y5, P7Y8, P10Y11, P14Y15. All experiments were performed according to the guidelines of the European Council Directive for the Care of Laboratory Animals.
Histology and Cell Count
For MN count, the spinal cord of mice was quickly dissected and fixed in Carnoy or Bouin solution (for mice older than P5) and processed for paraffin embedding. Serial transverse sections (8 Km thick for E18; 12 Km thick for P0Y1, P4Y5, and P7Y8; and 14 Km thick for P14Y15) were obtained through the entire lumbar segment of the spinal cord and stained with either Cresyl violet (E18Y5) or hematoxylin and eosin (P7Y15). Motoneurons were identified by their size and shape. The numbers of apparently healthy MNs and degenerating (pyknotic) cells in the ventral horn region were counted blindly on a side of every 10th section according to established procedures (37, 38) . For healthy MNs, only cells with a large nucleus and a visible clump of nucleolar material, along with a substantial cytoplasm, were counted. For pyknotic neurons, intact cells with condensation of nuclear chromatin, broken spherical profiles apparently engulfed by phagocytes, and rounded hyaline masses were counted. With these criteria, it was not necessary to use a correction factor to avoid double counting (38) . The numbers of MNs and pyknotic neurons counted were multiplied by 10 to estimate the total number of these cells per ventral horn.
Immunocytochemistry and Image Analysis
Lumbar spinal cords were fixed by immersion in 4% paraformaldehyde in 0.1 mol/L phosphate buffer (PB; pH 7.4) for 24 hours, cryoprotected with 30% sucrose in 0.1 mol/L PB, embedded in Tissue Freezing Medium (Triangle Biomedical Sciences, Durham, NC), and frozen. Transverse serial cryostat sections (10Y16 Km thick) were obtained and stored at j80-C.
Sections were sequentially rinsed in PBS containing 0.1% Triton X-100 for 30 minutes, blocked in 10% normal goat serum, and incubated with the primary antibody overnight at 4-C. The following primary antibodies were used: mouse monoclonal antiYphosphorylated neurofilament heavy chain (SMI-31; 1:1000; Abcam, Cambridge, United Kingdom), mouse monoclonal antiYnonphosphorylated neurofilament heavy chain (SMI-32; 1:1000; Abcam), rabbit polyclonal antiYvesicular glutamate transporter 1 (VGLUT1; 1:1000; Synaptic Systems, Göttingen, Germany), rabbit polyclonal antiYvesicular GABA transporter (VGAT; 1:500; Millipore, Temecula, CA), rabbit polyclonal anti-ionized calcium-binding adaptor molecule 1 (Iba1; 1:500; Wako Pure Chemical Industries Ltd, Osaka, Japan), rat monoclonal anti-mouse CD68 (1:100; AbD Serotec, Oxford, United Kingdom), rabbit polyclonal antiYglial fibrillary acidic protein (GFAP; 1:1000; Dako Cytomation, Glostrup, Denmark), chicken polyclonal anti-GFAP (1:1000; Abcam), mouse anti-synaptophysin (Syphys; 1:200; Millipore), and rabbit antiYphosphorylated myosin light chain (P-MLC; 1:250; Cell Signaling Technologies, Danvers, MA). The 2 antibodies to GFAP gave similar results and are referred to as ''anti-GFAP.'' After several washes, sections were incubated at room temperature for 1 30th section of the entire lumbar spinal cord were taken. The same scanning parameters were used for the acquisition of confocal images corresponding to the different experimental groups. Slides from the different animals were processed in parallel for immunocytochemistry and subsequent confocal imaging. Levels of GFAP and Iba1 immunoreactivity were quantified by digital image analysis using Visilog 6.3 software (Noesis, Orsay, France). The numbers of VGLUT1-, VGAT-, and P-MLCYimmunoreactive synaptic boutons on MN soma were manually counted on the screen. Only boutons in close contact with MNs showing a large nucleus, a visible nucleolus, and a healthy appearance were included in the counts, which were then normalized to the perimeter of MN soma. The areas of VGLUT1-and VGAT-positive boutons and the length of Syphys-immunoreactive terminals were also measured.
Electron Microscopy
Deeply anesthesized mice were transcardially perfused with cold saline serum followed by a freshly made solution containing 1% glutaraldehyde and 1% paraformaldehyde in 0.1 mol/L PB (pH 7.4). The spinal cord was dissected by dorsal laminectomy, and the lumbar segment was removed and placed in the same fixative overnight at 4-C. After washes with PB, samples were sectioned to obtain transverse slices that were postfixed with 1% OsO 4 for 2 hours, dehydrated, and embedded in EMbed 812 (Electron Microscopy Sciences, Fort Washington, PA). Ultrathin sections from selected areas, including ventral horns, were counterstained with uranyl acetate and lead citrate and observed with a Zeiss EM 910 (Zeiss, Oberkochen, Germany) electron microscope.
For analysis of dendrites, images of the spinal cord ventral horn at the neuropil area interposed between MN somata were randomly taken. Axosomatic synapses were studied after scoring systematically taken images of the periphery of MN cell bodies. Morphometry was performed using Visilog 6.3 software (Noesis). In transversally sectioned large dendrites, the following parameters were scored: occurrence of autophagosomes within dendrites; density, size, and type of axodendritic synapses; and frequency of autophagosomes in presynaptic terminals. In the sectioned soma of large MNs, the following parameters were analyzed: density, size, and type of axosomatic synapses; incidence of autophagosomes in presynaptic nerve terminals; and abundance of mitochondria. Axodendritic and axosomatic synapses were identified based on classical descriptions (39) but were slightly modified for immature mice spinal cord ultrastructure. Thus, MN afferent boutons were categorized as follows: Synapses with a thick postsynaptic density were classified as asymmetric; synapses with similar presynaptic and postsynaptic densities were classified as symmetric; and synapses containing a subsynaptic cistern were classified as C-terminal. A proportion of afferent boutons were scored as ''nonclassified.' ' 
Statistical Analysis
All quantitative data are expressed as mean T SE. Statistical analysis was performed with either Student t-test or one-way analysis of variance (ANOVA) followed by post hoc Bonferroni test. The level of significance was set at p G 0.05.
RESULTS
MN Loss in the Spinal Cord of SMN$7 Mice
A moderate but significant reduction in the number of MNs was observed in the lumbar spinal cord of SMN$7 mice. Motoneuron loss started between P0Y1 and P4Y5 (È20% of WT mice) and was slightly more prominent between P7Y8 and P14YP15 (Figs. 1AYC). Thus, there was an approximately 25% decrease in MN number on P14Y15 in SMN$7 versus WT animals. Counts of pyknotic (degenerating) cells, presumably MNs, in the ventral horn of P4Y5 and P14Y15 mice revealed significantly increased numbers in SMN$7 animals versus those in WT littermates (Figs. 1DYF) . In addition to the decrease in MN survival in the spinal cord of P7Y8 and P14Y15 mutants, SMN$7 MNs also showed a significant size reduction starting on P7Y8, becoming more marked on P14Y15 (Fig. 1G, compare Figs. 1B and C). Another histopathologic hallmark of MN diseases is the presence of abnormally phosphorylated neurofilament (40) . There was a significant increase (È58%) in the number of ventral horn MNs that are immunoreactive to SMI-31 antibody against phosphorylated neurofilament in SMN$7 mice on P14Y15 versus WT littermates (Figs. 1HYL) . Overall, these results suggest that spinal cord MNs progressively degenerate postnatally in mutant mice and that MN loss persists in the end stages.
Ultrastructural Pathology of MN Degeneration in SMN$7 Mice
Ultrastructural analysis of the spinal cord ventral horn of SMN$7 mice showed MN degeneration on P7Y8, which was more extensive at end stage (P14Y15). Most degenerating MNs did not have a typical apoptotic ultrastructure, such as the formation of circumferential electron-dense spheroids of highly (43) . Dendritic profiles immediately adjacent to these degenerating MNs seemed to undergo necrotic-like (possibly glutamate-mediated excitotoxicity -induced) changes because they appeared swollen and completely depleted of cellular organelles (Fig. 2B) , comparable to the description by Olney and Ishimaru (41) . These obvious and terminal degenerative changes seemed to be preceded by other more subtle alterations revealed by morphometric analysis (Table) , including mitochondrial depletion in apparently healthy SMN$7 MNs. Other involutional changes may herald terminal MN death in SMA. Indeed, there were increased numbers of autophagic vacuoles within MN afferent nerve terminals apposed to the soma and presumptive proximal dendrites (Figs. 3AYJ). Similar autophagic vacuoles were also observed on P7Y8 in WT synapses, but significantly less than in mutants (Figs. 3B, I, J). Further degenerative changes, such as altered synaptic vesicle morphology, were also observed in some SMN$7 axodendritic synapses (Fig. 3C) . Although nonsignificant, apparently increased numbers of autophagic organelles were also seen inside the dendritic profiles of mutant animals (Table) . A more detailed examination of different forms of autophagic vacuoles within dendrites suggested that they arise from the engulfment of degenerating presynaptic terminals, which are found inside autophagosomes (Figs. 3D, F) . Thus, at least in part, autophagic vacuoles within dendrites come from phagocytosis of adjacent degenerating presynaptic structures; therefore, their interpretation as heterophagic organelles should be considered (Fig. 3K) . All of these alterations indicate overall synaptic loss (Table) . Microglial profiles often enwrapped dendrites containing degenerating synapses, suggesting that they will be degraded further by microglial phagocytosis (Figs. 2E; 3E, F) . In fact, infiltrating microglial cells, some of which contained abundant large heterophagic inclusions, were observed in the ventral horn neuropil located between MN somata (Figs. 2C, D) .
Astroglial and Microglial Activation in the Ventral Horn of the Lumbar Spinal Cord of SMN$7 Mice
For analysis of astroglia and microglia, immunofluorescence studies were performed on sections of the lumbar spinal cord at different time points ranging from the newborn stage to the presymptomatic stage (P4Y5), early symptomatic stage (P7YP8), and end stage (P14Y15) of the disease. There was a significant increase in GFAP-positive astrocyte profiles surrounding MNs in the ventral horn of P4Y5 SMN$7 mice (Fig. 4A) . This astrocyte reaction persisted until the end stages and was more marked on P10Y11 and P14Y15 (Figs. 4AYC) . To determine whether there were differences in astroglial activation between the dorsal horn and the ventral horn, we performed immunofluorescence analysis with anti-GFAP antibody independently in the dorsal and ventral areas of the spinal cord of WT and SMN$7 animals. In P4Y5 mutant mice, astroglial activation was predominantly observed in the ventral horn, with the dorsal horn displaying immunoreactivity to GFAP similar to that observed in WT littermates (Figs. 4DYG, L) . In contrast, on P10Y11, notable astroglial activation was observed in both the dorsal horn and the ventral horn of SMN$7 mice (Figs. 4HYL) .
Immunofluorescence with anti-Iba1 antibody revealed an overt increase in the density of microglial cells in the lumbar spinal cord of SMN$7 versus WT animals. Diseased animals showed an increase (though not statistically significant) in Iba1-immunoreactive profiles around MNs on P4Y5. This increase was significant on P7Y8 and persisted until the late stage of the disease (Fig. 5A) . Interestingly, a high concentration of Iba1-positive profiles was observed adjacent to MNs in the ventral horn of SMN$7 animals (compare Figs. 5B and C). Colocalization studies with anti-Iba1 and anti-CD68 antibodies, as a marker for activated microglia (44) , were performed to assess the extent of microglial activation. We found a significant increase (È2.3-fold; p G 0.05) in the number of profiles showing both Iba1-and CD-68Ypositive immunoreactivity in the spinal cord of P7Y8 SMN$7 mice compared with their WT littermates, and this increase was even higher (È3-fold; p G 0.001) on P14Y15 (Figs. 5D, E) . This indicates that the increase in microglial cells observed in SMN$7 mice mostly corresponds to activated microglia.
Changes in Afferent Inputs to Spinal Cord MNs in SMN$7 Mice
Alterations in sensory-motor connectivity and glutamatergic synaptic afferents on MNs have been reported in distinct mouse models of SMA (25, 33, 34) . To explore whether there was a correlation between changes in glial reaction and the loss of MN afferent synapses in SMN$7 mice, we quantified the number of glutamatergic excitatory and GABAergic inhibitory synapses after immunofluorescence using anti-VGLUT1 and anti-VGAT antibodies, respectively (45) , in combination with fluorescent Nissl staining for MN identification. There was a significant decrease in VGLUT1 and VGAT synaptic boutons contacting MN somata from P0YP1 to P14YP15 in WT mice (Figs. 6A, D) . This decrease in bouton density cannot be attributed to the increase in MN size occurring during normal development because comparable results were obtained when the counts were referred to individual MN somata (data not shown). The gradual loss of central synapses on MNs at postnatal ages could in part be related to the programmed cell death of spinal interneurons in normal mice, which has been reported to occur postnatally in the rat (46) . VGLUT1 terminals on MNs of SMN$7 mice were found to be significantly reduced compared with WT littermates: These differences were already seen at embryonic stages (E18; È25% decrease in mutant mice in relation to WT animals; p G 0.05) and persisted at the postnatal stages of the disease, with a maximal loss (È37%; p G 0.001) on P0 to P1 (Figs. 6AYC) . Although an increase in the density of VGLUT1-positive boutons was found on SMN$7 MNs between E18 and P0YP1, these differences were not statistically significant; no significant changes in somatic VGLUT1 bouton density were found either when we compared mutant animals at the different postnatal ages. A significant reduction in the number of VGAT synaptic afferents on SMN$7 MNs was observed on P7Y8; however, in agreement with a previous report (25) , no differences were seen on P14Y15 (Figs. 6DYF) . Similar results were obtained when the numbers of VGLUT1-and VGAT-immunoreactive boutons on SMN$7 MNs were counted per individual MN soma (data not shown), indicating that the observed changes in bouton density were not caused by variations in MN size.
The area of presynaptic boutons was measured between P0Y1 and P14Y15. Although we found no changes in the size of VGAT-positive terminals in mutant mice compared with WT mice, there was a modest but significant reduction in the area of VGLUT1-containing boutons in P14 to P15 SMN$7 spinal cords (WT, 2.6 T 0.1 Km The involvement of microglia in afferent MN synaptic pruning seen in electron microscopy studies was also assessed by multiple immunofluorescence imaging. Immunostaining of CD68 can be used to highlight active phagocytosis in microglia (47) . When anti-CD68 antibody was combined with anti-VGLUT1 antibody, some presumably degenerating glutamatergic nerve terminals were visualized engulfed inside microglial cells in the spinal cord of SMN$7 mice (Figs. 6GYJ) .
Changes in MN synapses in SMN$7 mice were also quantified according to their ultrastructural features (39) (Figs. 7AYE) . The analysis of the different types of synapses corroborated the loss of symmetric terminals, which are presumably inhibitory (48) . Although we also saw an apparent reduction in asymmetric boutons apposed to SMN$7 MNs, this change did not reach statistical significance, possibly because of sampling variability. Interestingly, we observed a significant increase in C-type boutons on MNs of mutant mice (Fig. 7E) . These are cholinergic afferent inputs specific for >-MNs originating from a recently defined interneuronal group near the central canal (49) . The increase in C-type boutons on MNs may be the consequence of the sprouting of this particular class of nerve terminals to compensate for the loss of other afferent synaptic inputs. A similar phenomenon has been described in a mouse model of ALS (50Y53).
Upregulation of nNOS in MNs and Increased Phosphorylation of Myosin Light Chain in Afferent Synapses on MNs of SMN$7 Mice
Nitric oxide plays a role in synaptic remodeling in adult MNs by mediating synaptic loss from pathologic neurons (35, 54) . Thus, we investigated whether there was induction of nNOS in MNs as a possible cause of the synaptic remodeling in SMN$7 mice.
Neuronal NO synthase was increased in MNs (identified with SMI-32 antibody) of SMN$7 mice from P4Y5 to P14Y15 compared with age-matched WT animals (Figs. 8AYG) . Because NO activates the RhoA/ROCK pathway, which is essential for neurite retraction (36, 55, 56) , we hypothesized that this pathway participates in the loss of synapses on spinal cord MN somata in SMA. The final effector to induce actomyosin contraction and neurite retraction is P-MLC, a substrate of ROCK (57) . Therefore, we studied P-MLCYimmunoreactive boutons colocalizing with the presynaptic marker Syphys around MNs on P11 and found a decrease (È58%) in the linear density of Syphys-positive boutons on MNs in parallel with a dramatic increase (È71%) in the percentage of these boutons showing immunoreactivity to P-MLC (Figs. 8HYQ) .
DISCUSSION
In the present study, we report that MNs of SMN$7 mice undergo early and gradual degeneration that correlates with the progression of the clinical disease phenotype. Although MN death is only moderate, surviving MNs display cytologic changes indicative of cellular dysfunction, which starts long before overt MN loss. Alterations in MNs include significant defects in glutamatergic and GABAergic synaptic afferents accompanied by marked astroglial and microglial reactions in the lumbar spinal ventral horn. Dendrites and microglial cells were found to participate in the phagocytosis and clearance of degenerating afferent boutons. Concomitant with these alterations, nNOS was upregulated in MNs together with the activated RhoA/ROCK pathway, as deduced from the increase in P-MLC expression in synaptic afferents on MNs. These results suggest the involvement of nNOS and the RhoA/ ROCK pathway in the central synaptic loss occurring in SMA.
Overall, our observations suggest that the earliest (E18YP1) change occurring in the degenerative process in SMA is the loss of excitatory glutamatergic synaptic inputs to MNs. Reduced excitability may sensitize MNs to undergo degeneration and death, as has been demonstrated in the context of both ALS (51) and SMA (58) . Motoneuron death starts between P0 and P4, concomitant with an astroglial reaction and increased MN NO expression. Later, as MN death progresses, there occurs a microglial reaction that is involved in both the clearance of dying MNs and the removal of degenerating synapses.
Progressive MN Degeneration in the Spinal Cord of SMN$7 Mice
Progressive MN death has been considered a pathologic hallmark of human SMA. In agreement with previous studies in which different mouse models of SMA have been used (6, 12, 13, 16, 59Y61), we also found only moderate (although significant) MN loss in the spinal cord of SMN$7 mice. The reduction in the number of apparently healthy MNs in mutant animals begins between P0Y1 and P4Y5, coinciding with the appearance of the initial phenotypic changes (13) , and is more conspicuous at the end stage of the disease (P14YP15; Fig. 1A ). This time course of MN degeneration in SMN$7 mice contrasts with that reported by others. Thus, Le et al (6) showed some loss of MNs in the lumbar spinal cord on P9, but not on P4. Kariya et al (15) reported a significant reduction in the number of axons in the phrenic nerves and cervical ventral roots of SMN$7 animals, but loss of neither MNs nor motor axons in ventral roots was observed in the lumbar spinal cord even at the end stage (P14) of the disease. A possible explanation for these discrepancies could be the differences in the spinal cord segments used for MN count: Whereas the whole lumbar spinal cord was included in cell counting in our study, the abovementioned reports analyzed the loss of MNs and motor axons in the ventral roots of restricted spinal cord segments (i.e. L4YL5). Indeed, we found a substantial number of degenerating MNs in the most rostral segments of the lumbar spinal cord of P4Y5 and P14Y15 SMN$7 mice (unpublished observations). Indeed, a rostrocaudal gradient of MN loss has been described in the spinal cord of mice with SMA, with MNs located at the rostral levels being more susceptible to degeneration (15, 33) . We also observed that MN degeneration in affected animals was accompanied by accumulation of phosphorylated neurofilament (evidenced with SMI-31 antibody) and reduction in the soma size of apparently healthy cells. Interestingly, an increase in phosphorylated neurofilament in MNs has been shown in several neurodegenerative disorders, including the adult-onset MN disease ALS (40, 62) . Overall, the histopathologic alterations that we found in mutant mice suggest that even surviving SMN-deficient MNs are dysfunctional. This could explain, in part, the substantial degree of neuromuscular dysfunction found in diseased animals, especially in advanced disease stages, despite modest cell death (20%Y25% of initial MN populations in the lumbar spinal cord). In agreement with our results, the extent of MN loss has been shown to be limited in other mouse models of SMA (16, 63) . The independence of clinical signs from the activation of MN cell death pathways has also been reported in the ALS mouse model (52, 53, 64) . Our observation of increased numbers of pyknotic cells (presumptive MNs) at end stages in SMN$7 mice suggests that MN loss is still an ongoing process when animals die as a consequence of the disease.
Astroglial and Microglial Activation in the Spinal Cord of SMN$7 Mice
Neuroinflammation is a common process in a variety of neurodegenerative disorders that involves the activation of microglia, astrocytes, and, in some cases, T lymphocytes. Whereas neuroinflammation has been widely studied in ALS (20, 65) , data on neuroinflammation in SMA are very scarce (27) . Severe gliosis has been described in the anterior horns and ventral nerve roots of human SMA spinal cord tissue (66Y69), and we observed increased numbers of astroglial and microglial cells surrounding MNs in the spinal cord of SMN$7 mice. It has traditionally been thought that neuroinflammation is a secondary cellular event arising in response to neuronal loss. Glial reactions may have both beneficial and deleterious consequences on MNs, that is, gliosis sometimes acts to limit cell damage and to promote repair but astrocytes and microglia can initiate neurodegeneration under certain circumstances (24, 27, 65, 70, 71) . Our results are in agreement with those reported by Ling et al (25) , who showed microgliosis around MNs in SMN$7 mice. We further show that MN loss in diseased animals (which is already significant on P4YP5) precedes an overt microglial reaction, suggesting that microglial cells are not active players in MN death induction. It is more likely that microgliosis is a reactive process resulting from peripheral neuromuscular disconnection (i.e. synaptic stripping after peripheral nerve injury [72] ) and/or other forms of MN damage leading to cell death, similar to those occurring in other models of MN degeneration (73) . In fact, we observe an absence of microglial reaction around spinal cord MNs in Smn j/j ;SMN2 +/+ mice (a model of a more severe form of SMA) on P5Y6, an age corresponding to the end stage of the disease and in which MN loss is maximal (12) . In contrast, we have previously described astrogliosis in early stages of SMA, before the occurrence of a significant reduction in the number of MNs in Smn j/j ;SMN2 +/+ mice (12). This observation is consistent with our present data on SMN$7 mice. While the present article was in preparation, astrocytic changes were reported in vivo in SMN$7 mice and in vitro in SMA-induced pluripotent stem cells (26) ; McGivern et al (26) also found that SMA-induced pluripotent stem cellYderived astrocytes display higher basal calcium levels and increased calcium response to ATP. Overall, these data suggest that dysfunctional astrocytes could be important contributors to SMA pathogenesis by inducing and/or aggravating MN pathology. For example, we have previously shown that reactive astrocytes in the spinal cord of SMN$7 mice display an increased expression of the main components of the Notch signaling pathway, including the Notch ligand Jagged 1, leading to increased Notch signaling on adjacent MNs (74) . Interestingly, the expression of Jagged 1 on astrocytes in an inflammatory environment has been reported to be increased (75) . Indeed, astrocytes seem to play an important role in MN degeneration in ALS. Impaired functioning of astrocytic excitatory amino acid transporters in ALS results in excitotoxicity and neuronal cell death (76) . In addition to perturbation in glutamate handling, astrocytes in ALS exert direct toxic effects on MNs through the release of still unidentified factors (77Y79). Although these mechanisms remain to be explored in SMA, disruption of neurotrophic signaling mediated by the astrocytic secreted glial cell line Yderived neurotrophic factor has been reported (26) . Astrocytes are also endogenous regulators of basal transmission at central synapses (80) , through their ability to modulate intracellular calciumYdependent processes, and may play a role in network changes by influencing the retraction of synaptic boutons and by providing a proper perisynaptic environment (28, 81) . Astrocytes also play an active role in promoting synaptic differentiation and activity (82) . It will be interesting to examine whether astrocytic dysfunction in SMA affects their ability to promote synaptic activity, which seems to be crucial to the regulation of synaptic stability/elimination (83) .
Loss of Afferent Synapses on Spinal Cord MNs in SMN$7 Mice
We observed a gradual reduction in the density of central glutamatergic and GABAergic synapses on spinal cord MNs during normal postnatal development that could reflect naturally occurring synaptic remodeling; this requires further detailed studies. In support of this regressive event, we observed degenerating synaptic boutons in WT animals via electron microscopy. This phenomenon is exacerbated in SMA for both glutamatergic and, to a lesser extent, GABAergic nerve afferents. The increased loss of glutamatergic terminals in SMN$7 spinal cords is in agreement with previous studies (13, 25, 33, 34) . In contrast to some reports (25) but in accordance with Mentis et al (33) , we show that the loss of central synapses in SMA precedes MN death. Indeed, we found that glutamatergic deafferentation started at prenatal stages (E18), long before MN cell death was first detected (P4Y5). SMN-depleted PC-12 cells exhibit impaired neuritogenesis after never growth factor differentiation (84) , suggesting that impaired axonal growth cone migration may be involved in synaptic loss at prenatal stages. The loss of central synapses is a common process in neurodegenerative diseases (85) that occurs before MN death in ALS (52, 53, 86Y88) and has also been reported in patients with SMA (89, 90) . In addition to distal peripheral motor axons, it is conceivable that, after SMN deficiency, dying back may affect other neuronal types, leading to a broad synaptopathy involving large axons projecting to MNs. Indeed, reduced proprioceptive reflexes and synapses have been observed early in mice with SMA (33) , and growth cones from SMA dorsal root ganglion sensory neurons display reduced size and messenger RNA content (91) . However, the contribution of MN deafferentation to SMA pathogenesis remains controversial. In fact, different studies have reported that the defects in spinal cord synaptic connectivity observed in SMA could be considered a consequence of primary MN pathology (92Y94).
Via electron microscopy, we observed a reduction in afferent synaptic boutons on SMA MNs. Except for C-type boutons, the different types of synapses studied showed decreased numbers in relation to MN somatic membrane length; however, because of sampling variability, the results were statistically significant only for symmetric and C-type synapses. The C-type boutons are cholinergic synapses derived from interneurons located near the central canal (49) . Because these interneurons have short axons, their terminals should be less vulnerable to defects in axonal transport and dying-back degeneration, possibly explaining why they are not disrupted in SMA MNs. The loss of other types of synaptic boutons may create a vacant territory on MNs that is occupied by the sprouting of cholinergic premotor interneurons, leading to increased numbers of C-terminals.
One of the most conspicuous features observed in degenerating terminal synaptic boutons and contacting dendrites was the accumulation of autophagic vacuoles, as reported in other forms of neuronal injury (95) . Autophagic vacuoles were also occasionally seen in WT dendrites, presumably reflecting a postnatal remodeling of neural processes. Detailed examination of the ultrastructural morphology of synaptic degeneration in SMA revealed a novel mechanism involving neuronal (dendritic) phagocytosis of synapses, suggesting that degenerating afferent nerve terminals enriched with autophagosomes are engulfed by adjacent dendrites, which in turn appear to be incorporated into the MN cytoplasm. We observed a similar process in WT animals but to a much lesser extent, suggesting that synapse elimination in spinal cord MNs is an example of neuronal phagocytosis during normal postnatal synapse elimination that is exacerbated in SMA. Although the phagocytic capacity of neurons is not usually considered, it is a recognized phenomenon (96) , but it has not previously been related to synaptic elimination. These findings do not preclude the relevance of microglial cells to the clearance of cellular debris during synapse degeneration/elimination. Indeed, we detected active (amoeboid) microglial cells enwrapping structural complexes that include degenerating presynaptic terminals and postsynaptic dendrites (Fig. 2E) .
Increased nNOS in MNs as a Trigger of RhoA Pathway Activation and Synaptic Bouton Retraction
In addition to exacerbated neuronal phagocytosis in SMA, the loss of glutamatergic and GABAergic synapses on MNs could be the result of the induction of nNOS in MNs. In this regard, it has been reported that NO is ''necessary'' and ''sufficient'' to induce the detachment of synaptic afferents from MNs in response to physical injury to motor nerves and in ALS (54) . Moreover, it has been shown that nNOS upregulation after nerve injury triggers the loss of excitatory synaptic inputs to injured hypoglossal MNs (35, 97) . We report here that nNOS is upregulated in SMN$7 MNs, suggesting a role in the withdrawal of synaptic afferents found in our model. It has been proposed that, after motor nerve injury, NO produced via upregulation of nNOS would lead to activation of the RhoA/ROCK pathway (36) . Interestingly, this pathway has been shown to be abnormally increased in the SMA mouse model, and treating SMA mice with a ROCK inhibitor led to improved maturation of the neuromuscular junction and dramatically increased the life span of animals (98) . Phosphorylated myosin light chain is the final effector of the RhoA/ROCK pathway and is known to trigger actomyosin contraction and neurite retraction (55, 56) , thus leading to synaptic detachment/synaptic bouton retraction (36) . Therefore, we propose that the NO released from SMA MNs could trigger the observed increase in the phosphorylation of synaptic myosin light chain around these cells, contributing to afferent synapse loss.
